Inventors list |
Agents list |
Assignees list |
List by place |
Classification tree browser |
Top 100 Inventors |
Top 100 Agents |
Top 100 Assignees |
GENENTECH, INC.
SOUTH SAN FRANCISCO, CA US
1. 20090293137 Novel Gene Disruptions, Compositions and Methods Relating Thereto 11-26-20092. 20090288176 Novel Gene Disruptions, Compositions and Methods Relating Thereto 11-19-2009
3. 20090286258 ANALYSIS OF ANTIBODY DRUG CONJUGATES BY BEAD-BASED AFFINITY CAPTURE AND MASS SPECTROMETRY 11-19-2009
4. 20090285837 HER2 ANTIBODY COMPOSITION - composition comprising a main species HER2 antibody that binds to domain II of HER2 and an amino acid sequence variant 11-19-2009
5. 20090285830 ANTIBODIES TO LYMPHOTOXIN-ALPHA - The invention provides various antibodies that bind to lymphotoxin 11-19-2009
6. 20090270595 IL-1 RELATED POLYPEPTIDES - novel polypeptides having homology to the IL-1-like family of proteins and to nucleic acid molecules encoding those 10-29-2009
7. 20090269811 IL-1 RELATED POLYPEPTIDES - novel polypeptides having homology to the IL-1-like family of proteins and to nucleic acid molecules encoding those 10-29-2009
8. 20090269351 METHOD OF DIAGNOSING AND TREATING GLIOMA 10-29-2009
9. 20090269339 RESPONSES TO IMMUNIZATIONS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH A CD20 ANTIBODY 10-29-2009
10. 20090269338 HUMANIZED ANTI-FACTOR D ANTIBODIES AND USES THEREOF 10-29-2009
11. 20090264370 POLYPEPTIDES HOMOLOGOUS TO VEGF AND BMP1 10-22-2009
12. 20090258025 TREATMENTS AND DIAGNOSTICS FOR CANCER, INFLAMMATORY DISORDERS AND AUTOIMMUNE DISORDERS 10-15-2009
13. 20090258013 NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES 10-15-2009
14. 20090246173 TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies 10-01-2009
15. 20090239236 GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO AN EGFR ANTAGONIST CANCER THERAPY 09-24-2009
16. 20090226465 MACROCYCLIC DEPSIPEPTIDE ANTIBODY-DRUG CONJUGATES AND METHODS 09-10-2009
17. 20090221630 IAP INHIBITORS - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have 09-03-2009
18. 20090220504 COMBINATORIAL THERAPY - the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular 09-03-2009
19. 20090214564 ANTI-EPHRINB2 ANTIBODIES AND METHODS USING SAME 08-27-2009
20. 20090209732 Secreted and Transmembrane Polypeptides and Nucleic Acids Encoding the Same 08-20-2009
21. 20090208500 Method of producing antibodies with improved function 08-20-2009
22. 20090204489 BIOLOGICAL MARKERS PREDICTIVE OF RHEUMATOID ARTHRITIS RESPONSE TO B-CELL ANTAGONISTS 08-13-2009
23. 20090202546 COMPOSITION COMPRISING ANTIBODY THAT BINDS TO DOMAIN II OF HER2 AND ACIDIC VARIANTS THEREOF 08-13-2009
24. 20090202536 ANTIBODY-DRUG CONJUGATES AND METHODS - antibody-drug conjugate compounds of Formula I: Ab 08-13-2009
25. 20090196876 Novel Gene Disruptions, Compositions and Methods Relating Thereto 08-06-2009
26. 20090192289 OMI PDZ MODULATORS - The invention provides modulators of Omi PDZ-ligand interaction, and methods of identifying and using these modulators 07-30-2009
27. 20090191215 Treatment with anti-VEGF Antibodies - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies 07-30-2009
28. 20090191209 METHODS AND COMPOSITIONS FOR TARGETING POLYUBIQUITIN 07-30-2009
29. 20090191184 DcR3 polypeptide, A TNFR homolog - TNFR homolog, identified as DcR3, is provided 07-30-2009
30. 20090186812 Apo-2 ligand - novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided 07-23-2009
31. 20090186409 COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR 07-23-2009
32. 20090186363 COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR 07-23-2009
33. 20090186018 COMPOSITIONS AND METHODS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS 07-23-2009
34. 20090181024 NOVEL COMPOSITION AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES 07-16-2009
35. 20090176822 PYRROLIDINE INHIBITORS OF IAP - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the 07-09-2009
36. 20090175865 CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES 07-09-2009
37. 20090175855 NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES 07-09-2009
38. 20090175854 Methods of using death receptor ligands and CD20 antibodies 07-09-2009
39. 20090169569 APO-2L receptor agonist and CPT-11 synergism 07-02-2009
40. 20090169556 VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS 07-02-2009
41. 20090169550 THERAPY OF RITUXIMAB-REFRACTORY RHEUMATOID ARTHRITIS PATIENTS 07-02-2009
42. 20090163419 Human growth hormone aqueous formulation 06-25-2009
43. 20090162364 Apo-2 ligand - novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided 06-25-2009
44. 20090155807 C-MET MUTATIONS IN LUNG CANCER - The invention provides methods and compositions useful for detecting mutations in c-met in lung cancer cells 06-18-2009
45. 20090155259 EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS 06-18-2009
46. 20090155247 Methods of Using Death Receptor Agonists and EGFR Inhibitors 06-18-2009
47. 20090148921 Compositions and methods for enhancing apoptosis 06-11-2009
48. 20090148457 HEPATOCYTE GROWTH FACTOR RECEPTOR ANTAGONISTS AND USES THEREOF 06-11-2009
49. 20090148448 METHODS AND COMPOSITIONS FOR MODULATING AND DETECTING WISP ACTIVITY 06-11-2009
50. 20090148435 ANTIBODY PURIFICATION BY CATION EXCHANGE CHROMATOGRAPHY 06-11-2009
51. 20090142786 SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME 06-04-2009
52. 20090142348 Novel Gene Disruptions, Compositions and Methods Relating Thereto 06-04-2009
53. 20090142259 Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors 06-04-2009
54. 20090137476 Apo-2 ligand variants and uses thereof - The disclosure provides Apo-2 ligand variant polypeptides 05-28-2009
55. 20090136997 PRO1550 POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME 05-28-2009
56. 20090136492 THERAPY OF OCULAR DISORDERS - The present application describes therapy of ocular disorders using antagonists, such as antibodies, that bind to CD2 05-28-2009
57. 20090131407 TETRACYCLIC KINASE INHIBITORS - The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment 05-21-2009
58. 20090123930 METHODS AND COMPOSITIONS FOR DIAGNOSTIC USE IN CANCER PATIENTS 05-14-2009
59. 20090098112 NOVEL ANTIBODIES - the use of VEGF antagonists and a novel anti 04-16-2009
60. 20090087428 ANTI-FC-GAMMA RIIB RECEPTOR ANTIBODY AND USES THEREFOR 04-02-2009
61. 20090087426 Methods for Treatment of Allergic Asthma 04-02-2009
62. 20090083866 TRANSGENIC ROSA26-LUCIFERASE MICE FOR BIOLUMINESCENT IMAGING 03-26-2009
63. 20090081232 METHODS OF TREATING DISEASES WITH ANTI-VEGF ANTIBODIES 03-26-2009
64. 20090081229 ANTI-PRO87299 ANTIBODIES - compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune 03-26-2009
65. 20090081223 FIXED DOSING OF HER ANTIBODIES - The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab 03-26-2009
66. 20090075317 METHODS AND COMPOSITIONS FOR MODULATING HEPATOCYTE GROWTH FACTOR ACTIVATION 03-19-2009
67. 20090068178 Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin 03-12-2009
68. 20090068110 ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR RECEPTOR 03-12-2009
69. 20090054631 COMPOSITIONS AND METHODS FOR TREATMENT OF NON-HODGKIN'S LYMPHOMA 02-26-2009
70. 20090054624 PRO1190 POLYPEPTIDES - novel polypeptides having homology to CDO protein and to nucleic acid molecules encoding those polypeptides 02-26-2009
71. 20090053230 ANTI-OX40L ANTIBODIES AND METHODS USING SAME 02-26-2009
72. 20090053216 Treatment with Anti-VEGF Antibodies - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies 02-26-2009
73. 20090048313 2-AMIDO-THIAZOLE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF 02-19-2009
74. 20090047291 MODULATORS OF HEPATOCYTE GROWTH FACTOR ACTIVATOR 02-19-2009
75. 20090041788 Apo-2L receptor agonist and CPT-11 synergism 02-12-2009
76. 20090041749 Compositions and methods for the diagnosis and treatment of tumor 02-12-2009
77. 20090041742 HUMAN DNASE II - This invention relates to a novel human deoxyribonuclease, referred to as human DNase II 02-12-2009
78. 20090028856 Anti-CD79B Antibodies and Immunoconjugates and Methods of Use 01-29-2009
79. 20090023602 BINDING POLYPEPTIDES WITH RESTRICTED DIVERSITY SEQUENCES 01-22-2009
80. 20090022713 ANTI-PRO87299 ANTIBODIES - compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune 01-22-2009
81. 20090012003 POLYPEPTIDES HOMOLOGOUS TO VEGF AND BMP1 01-08-2009
82. 20090010925 ANTIBODY VARIANTS - of parent antibodies are disclosed which have one or more amino acids inserted in a hypervariable region of the parent antibody and 01-08-2009
83. 20090010924 Apoptotic Anti-IgE Antibodies - The present application relates to apoptotic anti-IgE antibodies nucleic acid encoding the same 01-08-2009
84. 20090010883 TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies 01-08-2009
85. 20090010881 TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies 01-08-2009
86. 20090004204 Assays and methods using biomarkers - Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are 01-01-2009
87. 20090004189 BIOLOGICAL MARKERS PREDICTIVE OF RHEUMATOID ARTHRITIS RESPONSE TO B-CELL ANTAGONISTS 01-01-2009
88. 20080318989 Pyrimidine Kinase Inhibitors - The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment 12-25-2008
89. 20080318800 METHODS AND COMPOSITIONS FOR DETECTING AUTOIMMUNE DISORDERS 12-25-2008
90. 20080317758 Polypeptide variants with altered effector function 12-25-2008
91. 20080317753 SELECTING PATIENTS FOR THERAPY WITH A HER INHIBITOR 12-25-2008
92. 20080311134 CYSTEINE ENGINEERED ANTI-MUC16 ANTIBODIES AND ANTIBODY DRUG CONJUGATES 12-18-2008
93. 20080311107 Novel Gene Disruptions, Compositions and Methods Relating Thereto 12-18-2008
94. 20080305106 Novel Gene Disruptions, Composition and Methods Relating Thereto 12-11-2008
95. 20080299136 WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS 12-04-2008
96. 20080299119 POLYPEPTIDES HOMOLOGOUS TO VEGF AND BMP1 12-04-2008
97. 20080299117 Treatment Method - The invention provides methods of treating autoimmune diseases using lower doses of anti-CD20 antibodies of 100 mg to 200 mg 12-04-2008
98. 20080299116 Vascular Endothelial Cell Growth Factor Antagonists and Uses Thereof 12-04-2008
99. 20080299115 Antibody Variants with Faster Antigen Association Rates 12-04-2008
100. 20080293121 HUMAN DNASE I HYPERACTIVE VARIANTS - amino acid sequence variants of human DNase I that have increased DNA-hydrolytic activity 11-27-2008
101. 20080292631 TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies 11-27-2008
102. 20080292630 TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies 11-27-2008
103. 20080286271 Methods and Compositions for Modulating Tweak and Fn14 Activity 11-20-2008
104. 20080280856 Fibroblast Activation Protein Inhibitor Compounds and Methods 11-13-2008
105. 20080279860 Treatment With Anti-VEGF Antibodies - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies 11-13-2008
106. 20080274993 Methods and compositions for modulating vascular integrity 11-06-2008
107. 20080274506 POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION 11-06-2008
108. 20080274108 POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION 11-06-2008
109. 20080274105 POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION 11-06-2008
110. 20080267968 TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies 10-30-2008
111. 20080254024 ANTI-EPHB2 ANTIBODIES AND METHODS USING SAME 10-16-2008
112. 20080248049 TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies 10-09-2008
113. 20080248037 Dr5 Antibodies and Uses Thereof - The application provides antibodies which specifically bind to DR5 receptor 10-09-2008
114. 20080248036 TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies 10-09-2008
115. 20080247951 ANTI-ROBO4 ANTIBODIES AND USES THEREFOR - The invention provides anti-Robo4 antibodies and compositions comprising the antibodies and methods of using 10-09-2008
116. 20080242709 2-AMIDO-4-ISOXAZOLYL THIAZOLE COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF 10-02-2008
117. 20080242655 AZA-INDOLYL COMPOUNDS AND METHODS OF USE 10-02-2008
118. 20080241159 METHODS AND COMPOSITIONS FOR SELECTIVE MODULATION OF VASCULARIZATION 10-02-2008
119. 20080241148 TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies 10-02-2008
120. 20080241146 Apo-2 ligand-anti-Her-2 antibody synergism 10-02-2008
121. 20080241143 Inhibition of leukocyte adhesion - This invention relates to the inhibition of intercellular adhesion mediated by L-selectin by administering a newly 10-02-2008
122. 20080233646 Human DR4 antibodies and uses thereof - Human Death Receptor 4 antibodies are provided 09-25-2008
123. 20080227119 ELISA for VEGF - The vascular endothelial growth factor activity in a patient's bloodstream or other biological sample can serve as a diagnostic and 09-18-2008
124. 20080226629 ANTI-VEGF ANTIBODIES - Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed 09-18-2008
125. 20080226621 ANTAGONIST ANTI-NOTCH3 ANTIBODIES AND THEIR USE IN THE PREVENTION AND TREATMENT OF NOTCH3-RELATED DISEASES 09-18-2008
126. 20080221014 Method of Diagnosing and Treating Glioma 09-11-2008
127. 20080220471 Vectors and Methods Using Same - vectors and to methods of using same 09-11-2008
128. 20080213837 Apo-3 ligand polypeptide - tumor necrosis factor and lymphotoxin homolog having apoptotic activity, identified as Apo-3 Ligand, is provided 09-04-2008
129. 20080213280 THERAPY OF AUTOIMMUNE DISEASE IN A PATIENT WITH AN INADEQUATE RESPONSE TO A TNF-ALPHA INHIBITOR 09-04-2008
130. 20080213268 NEUROPILIN ANTAGONISTS - Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed 09-04-2008
131. 20080206243 Methods for Treating Kidney Disorders - Provided are methods of treating kidney disorders in a subject by administering an effective amount of VEGFR 08-28-2008
132. 20080200375 Angiogenesis using hepatocyte growth factor 08-21-2008
133. 20080199464 Combination Therapy with Angiogenesis Inhibitors 08-21-2008
134. 20080199423 Methods of Using Apo2l Receptor Agonists and Ink Cell Activators 08-21-2008